As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers in the health care system, according to policymakers and experts, will do nothing to actually lower prescription drug costs for employers, health plans, or patients.

Instead there is consensus among policymakers and economic and health care experts that proposals targeting pharmacy benefit companies will:

• Increase prescription drug costs and spending,
• Undermine employer and health plan choice and flexibility, and
• Hand a huge financial win to Big Pharma by restricting PBMs ability to counter drug companies’ otherwise limitless pricing power.

See what current and former lawmakers had to say…

Experts caution against the costly effects of disrupting the market by passing anti-PBM bills…

###

PCMA is the national association representing America’s pharmacy benefit companies. Pharmacy benefit companies are working every day to secure savings, enable better health outcomes, and support access to quality prescription drug coverage for more than 275 million patients. Learn more at www.pcmanet.org